NAMA
NTLA icon

Nikko Asset Management Americas’s Intellia Therapeutics NTLA Stock Holding History

Nikko Asset Management Americas’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3M Sell
1,973,061
-219,400
-10% -$2.79M 0.36% 56
2025
Q4 		$19.7M Sell
2,192,461
-162,395
-7% -$2.24M 0.23% 75
2025
Q3 		$40.6M Sell
2,354,856
-316,409
-12% -$3.9M 0.39% 56
2025
Q2 		$25M Sell
2,671,265
-154,096
-5% -$1.27M 0.25% 69
2025
Q1 		$20M Sell
2,825,361
-167,302
-6% -$1.69M 0.26% 65
2024
Q4 		$34.9M Sell
2,992,663
-155,734
-5% -$2.43M 0.38% 53
2024
Q3 		$64.7M Sell
3,148,397
-109,292
-3% -$2.52M 0.73% 37
2024
Q2 		$72.9M Sell
3,257,689
-141,629
-4% -$3.37M 0.84% 33
2024
Q1 		$93.4M Sell
3,399,318
-79,244
-2% -$2.2M 0.93% 31
2023
Q4 		$106M Sell
3,478,562
-41,733
-1% -$1.2M 1.02% 25
2023
Q3 		$111M Buy
3,520,295
+125,639
+4% +$4.87M 1.33% 22
2023
Q2 		$138M Buy
3,394,656
+281,692
+9% +$11.4M 1.46% 21
2023
Q1 		$111M Buy
3,112,964
+136,962
+5% +$5.37M 1.28% 21
2022
Q4 		$104M Buy
2,976,002
+12,074
+0.4% +$574K 1.49% 20
2022
Q3 		$164M Buy
2,963,928
+182,792
+7% +$11.3M 2.1% 16
2022
Q2 		$141M Sell
2,781,136
-91,133
-3% -$4.63M 1.74% 15
2022
Q1 		$192M Buy
2,872,269
+118,366
+4% +$10M 1.41% 20
2021
Q4 		$328M Buy
2,753,903
+353,970
+15% +$44.3M 1.72% 18
2021
Q3 		$322M Sell
2,399,933
-663,516
-22% -$100M 1.38% 23
2021
Q2 		$507M Sell
3,063,449
-1,779,821
-37% -$139M 1.99% 15
2021
Q1 		$389M Sell
4,843,270
-261,092
-5% -$17.5M 1.9% 14
2020
Q4 		$278M Sell
5,104,362
-958,154
-16% -$34.8M 1.58% 20
2020
Q3 		$122M Sell
6,062,516
-121,031
-2% -$2.52M 1.08% 32
2020
Q2 		$124M Sell
6,183,547
-907,716
-13% -$15.4M 1.62% 18
2020
Q1 		$86.7M Sell
7,091,263
-87,257
-1% -$1.18M 1.61% 21
2019
Q4 		$105M Sell
7,178,520
-61,217
-0.8% -$852K 1.66% 18
2019
Q3 		$96.7M Buy
7,239,737
+2,078,639
+40% +$33.1M 1.72% 17
2019
Q2 		$84.5M Buy
5,161,098
+4,089,744
+382% +$64.3M 1.66% 18
2019
Q1 		$18.3M Buy
1,071,354
+1,065,374
+17,816% +$15.9M 0.48% 45
2018
Q4 		$82K Buy
5,980
+995
+20% +$18.5K ﹤0.01% 124
2018
Q3 		$141K Buy
+4,985
New +$145K ﹤0.01% 125

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nikko Asset Management Americas's NTLA Position: Q1 2026 in Review

Nikko Asset Management Americas reduced its Intellia Therapeutics (NTLA) stake by 10% in Q1 2026, selling an estimated $2.79M and leaving 1,973,061 shares worth $25.3M. The position accounts for 0.36% of the portfolio, ranked #56.

Nikko Asset Management Americas first reported a position in NTLA in Q3 2018 and has held it in 31 quarters since. The position peaked at $507M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Nikko Asset Management Americas held 1,973,061 shares of Intellia Therapeutics worth $25.3M as of Q1 2026.
  • Nikko Asset Management Americas sold 219,400 Intellia Therapeutics shares in Q1 2026, an estimated $2.79M.
  • Intellia Therapeutics made up 0.36% of Nikko Asset Management Americas's portfolio in Q1 2026, its #56 holding.
  • Nikko Asset Management Americas first reported a position in Intellia Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • Nikko Asset Management Americas's Intellia Therapeutics position peaked at $507M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Nikko Asset Management Americas's 13F filing for Q1 2026, filed 7 May 2026.